Autolus Therapeutics (NASDAQ:AUTL) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Autolus Therapeutics (NASDAQ:AUTL) issued its earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10), Zacks reports. During the same period in the prior year, the business posted ($0.26) EPS.

Autolus Therapeutics Price Performance

Shares of AUTL traded down $0.06 during trading hours on Wednesday, reaching $3.27. 990,899 shares of the company traded hands, compared to its average volume of 1,427,670. The stock has a fifty day simple moving average of $3.97 and a 200 day simple moving average of $4.00. Autolus Therapeutics has a fifty-two week low of $3.06 and a fifty-two week high of $7.45. The stock has a market capitalization of $870.11 million, a PE ratio of -2.77 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.